Clinical efficacy of thoracoscopic anatomical segmentectomy combined with Xiaoaiping injection on non-small cell lung cancer and its impacts on serum CYFRA21-1 and CA125 levels
LI Li-bin,SHI Jia-xing,WANG Zhen-hui
Department of External Surgery, Xingtai General Hospital, North China Medical and Health Group, Xingtai 054000, China
Abstract:
Objective To investigate the clinical efficacy of thoracoscopic anatomic segmental lung resection combined with Xiaoaiping injection in the treatment of non-small cell lung cancer (NSCLC) and the effects on cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and carbohydrate antigen 125 (CA125) levels. Methods A total of 103 NSCLC patients in our hospital were divided into observation group and control group, both groups received thoracoscopic anatomic segmental, and the observation group was combined with Xiaoaiping injection on this basis. Lung function, serum indexes, inflammatory factors, immune function and adverse reactions were compared between the two groups. Results After treatment, the pulmonary function indexes [maximal voluntary ventilation (MVV), forced vital capacity (FVC), Forced Expiratory Volume in 1 second (FEV1)] of both groups decreased significantly compared with those before operation (P <0.05), but the postoperative values of the observation group were significantly higher than those of the control group (P <0.05). The levels of serum CYFRA21-1 and CA125 and inflammatory factors [C-reactive protein (CRP), procalcitonin (PCT)] in the observation group were significantly lower than those in the control group (P <0.05). The CD3+, CD4+ and CD4+/CD8+ ratios in the observation group were significantly higher than those in the control group (P <0.05), and there was no significant difference in the incidence of adverse reactions between the two groups (P >0.05). Conclusion Thoracoscopic anatomic segmental combined with Xiaoaiping injection can reduce the decline in lung function after surgery, improve immune function, and reduce serum tumor markers and inflammatory factor levels in NSCLC patients.
